13 results about "Parathyroid gland" patented technology

The utility model discloses a kind of parathyroid gland detection devices, belong to medical instrument technical field, including limiting component, installation shell, light guide beam, signal conversion component, light transmission component and connecting lens, installation shell upper end is installed with light guide beam, light guide beam other end is connected with light source, limiting component is installed in installation shell one end, signal transmission cable is installed in limiting component, connecting lens is installed in installation shell other end, light transmission component is installed in installation shell inside, light transmission component one end is opposite connecting lens, light transmission component other end is connected with signal conversion component. Solve the problem that it is easy to be miscut due to the position of parathyroid gland cannot be detected clearly in the prior art. Improve the accuracy of thyroid surgery, prevent the occurrence of complications.

A parathyroid gland perfusion preservation device is provided, which relates to the field of human organ preservation technologies. The device includes a parathyroid gland preservation box, a perfusion liquid circulation system and a control system. The parathyroid gland preservation box defines a space for placing parathyroid glands. The perfusion liquid circulation system is connected to the parathyroid glands stored in the parathyroid gland preservation box through inlet pipes, indwelling needles and a reflux pipe to supply perfusion liquid to the parathyroid glands. The control system is electrically connected to components of the perfusion liquid circulation system, and configured to receive a working state signal of the components of the perfusion liquid circulation system, and send a control instruction to the components of the perfusion liquid circulation system according to the working state signal. The device can achieve in vitro preservation of parathyroid glands, and can effectively protect the parathyroid glands.

This invention belongs to the field of biosensor detection technology, specifically disclosing a carbon dot probe for detecting parathyroid hormone, its preparation method, and its application. The carbon dot probe provided by this invention comprises carbon dots and monoclonal antibodies 1 and 2 covalently coupled to the carbon dot surface. Monoclonal antibodies 1 and 2 specifically recognize the N-terminal and C-terminal epitopes of the parathyroid hormone molecule, respectively. The carbon dots possess aggregation-induced emission (AIE) properties and photosensitivity. This invention's carbon dot probe can achieve a highly sensitive, highly specific, rapid, and dual-mode visual detection method for parathyroid hormone by detecting the dual signal changes of aggregation-induced emission fluorescence enhancement and photocatalytic TMB color development induced by PTH-induced specific aggregation. This invention also provides carbon dots with aggregation-induced emission properties and photosensitivity, as well as a method for preparing the carbon dot probe for detecting parathyroid hormone.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.

This invention relates to the field of biomedicine, disclosing a long-acting pTH polypeptide compound and its preparation and application. The polypeptide has an octadecanoic acid or eicosanoic acid and its derivatives modified by at least one amino acid residue at the 13th, 26th, and 27th amino acid residues of the pTH (1-34) parent peptide sequence, and is covalently bound to the polypeptide backbone via an AEEA-AEEA-γ-Glu linker. This invention significantly enhances the binding ability of the polypeptide to serum albumin and prolongs its half-life by utilizing fatty acid side chain modification. The long-acting pTH polypeptide compound of this invention exhibits significant osteogenic activity, promoting the proliferation of MC3T3-E1 cells and generating osteogenic markers and calcium nodules under osteogenic induction conditions, with a 2-6 fold increase in binding ability to serum albumin. This invention also provides a solid-phase synthesis method for this polypeptide compound and a pharmaceutical composition containing it, which can be used to treat osteoporosis and hypoparathyroidism, effectively solving the compliance problem of existing drugs requiring daily injections.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

Disclosed are methods of preventing or reducing loss of kidney function in a chronic kidney disease (CKD) patient having secondary hyperparathyroidism (SHPT).

The present invention relates to non-invasive methods of diagnosing primary aldosteronism (PA), preferably in subjects in need of such diagnosis. As described herein, it was discovered that the concentration of plasma parathyroid hormone (PTH) in blood samples isolated from subjects was predictive of a diagnosis of primary aldosteronism depending on the plasma aldosterone concentration (PAC), plasma renin concentration (PRC), and plasma renin activity (PRA). Preferably PAC, PRC, and PRA are measured from the same blood sample as the concentration of plasma parathyroid hormone.

This application provides an integrated system for rapid detection and data analysis of parathyroid hormone, relating to the field of intelligent medical technology. The system includes: a detection unit configured to receive a patient's bodily fluid sample and perform rapid quantitative detection of parathyroid hormone, outputting a detection signal within a single detection cycle; an analysis unit configured to receive the detection signal and convert it into corresponding hormone concentration data; and a decision support unit comprising: an individualized baseline module configured to establish an individualized hormone concentration reference baseline for the patient based on at least one historical detection data of the target patient under a specific physiological or pathological state; a dynamic comparison module configured to compare and analyze the trend of real-time hormone concentration data obtained from subsequent detections of the patient with the individualized reference baseline to obtain comparison results; and a diagnostic and treatment assistance prompt module configured to generate prompt information to assist in clinical diagnosis or disease assessment based on the comparison results.